1INN logo

innoscripta Stock Price

Symbol: XTRA:1INNMarket Cap: €997.0mCategory: Software

1INN Share Price Performance

1INN Community Fair Values

    Recent 1INN News & Updates

    No updates

    innoscripta SE Key Details

    €78.8m

    Revenue

    €21.3m

    Cost of Revenue

    €57.5m

    Gross Profit

    €24.8m

    Other Expenses

    €32.7m

    Earnings

    Last Reported Earnings
    Mar 31, 2025
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    3.27
    Gross Margin
    72.97%
    Net Profit Margin
    41.47%
    Debt/Equity Ratio
    12.7%

    innoscripta SE Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About 1INN

    Founded
    2012
    Employees
    477
    CEO
    Michael Hohenester
    WebsiteView website
    innoscripta.com

    innoscripta SE provides software-as-a-service for managing research and development (R&D) tax incentives and project management consulting in Germany. It offers innoscripta Platform, which offers solutions to support its customers in identifying, validating, and managing R&D projects, as well as preparing R&D tax incentives applications. The company was incorporated in 2012 and is headquartered in Munich, Germany. innoscripta SE operates as a subsidiary of Hohenester Beteiligungs-Ug (Haftungsbeschränkt).

    German Market Performance

    • 7 Days: -0.2%
    • 3 Months: -1.3%
    • 1 Year: 19.8%
    • Year to Date: 4.7%
    In the last week, the market has stayed flat, however the Communication Services sector stood out, gaining 13%. As for the longer term, the market has risen 20% in the past 12 months. Looking forward, earnings are forecast to grow by 17% annually. Market details ›
    This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
    Continue reading